The Government has reaffirmed its commitment to strengthening Kenya’s health security through local vaccine production, with the first vial expected to be manufactured by 2027.
Speaking during a meeting with AIM Co. Ltd, a global vaccine manufacturer, Principal Secretary for Medical Services, Dr. Ouma Oluga, said the move is part of Kenya’s long-term strategy to reduce reliance on imports and position the country as a regional hub for vaccine development.
“Our vision is to ensure that by 2027, Kenya will have produced its first locally manufactured vaccine vial. This will not only boost our capacity to respond to health emergencies but also create a sustainable pharmaceutical manufacturing ecosystem,” said Dr. Oluga.
The discussions with AIM Co. Ltd focused on partnership modalities, technology transfer, and building local capacity for vaccine production.
The AIM delegation was led by the company’s Founder, Board Chair and CEO, Mr. Yan Zhou, alongside President Mr. Jia Shaojun, Vice President Ms. Joanna Wenjuan Zhou, Director Ms. Chloe Deng Wei, and International Business Manager Ms. Nicole Wan Li.
Also present were AIM’s local partners Livelite Ltd, represented by CEO Michael Asola, VP China and South East Asia George Hu, VP Global Business Development (USA) Louis Antoniu, Business Development Officer Tom Warenga, and Director of Partnerships Anthony Ochieng.
